Morepen posts record Q1 FY27 revenue of Rs. 575.31 Cr and PAT of Rs. 56.35 Cr as EBITDA jumps 207%
AI Market Summary
Morepen Laboratories reported record Q1'FY27 revenue and sharply higher profitability, with EBITDA margin expansion and strong export/API momentum. The move of its Rs. 825 Cr CDMO mandate into full commercialization, alongside initial commercial dispatches and clean USFDA inspection outcomes, signals improved operating leverage and execution on strategy. Market impact should be localized given the company-specific nature and limited linkage to major listed proxies here.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.24%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Morepen Laboratories reported record quarterly revenue of Rs. 575.31 Cr for Q1 FY27 ended June 30, 2026, up 34% YoY, and PAT of Rs. 56.35 Cr, up 394% YoY. EBITDA rose 207% YoY to Rs. 87.72 Cr, lifting the EBITDA margin to 15.25% from 6.65% in Q1 FY26. The company said its Rs. 825 Cr CDMO mandate has entered the full-scale commercialization phase, with Rs. 58 Cr of commercial CDMO dispatches completed in Q1 FY27.
